| pubmed-article:11564371 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11564371 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11564371 | lifeskim:mentions | umls-concept:C0949691 | lld:lifeskim |
| pubmed-article:11564371 | lifeskim:mentions | umls-concept:C0725066 | lld:lifeskim |
| pubmed-article:11564371 | lifeskim:mentions | umls-concept:C0332185 | lld:lifeskim |
| pubmed-article:11564371 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11564371 | pubmed:dateCreated | 2001-9-20 | lld:pubmed |
| pubmed-article:11564371 | pubmed:abstractText | The observation that anti-tumor necrosis factor (anti-TNF) therapies dramatically reduce joint pain and inflammation and retard radiographic progression in rheumatoid arthritis (RA) has created a considerable amount of enthusiasm among rheumatologists and has set new treatment standards for patients with inflammatory joint disease. A central question that has emerged is whether these agents are effective in treating the seronegative spondyloarthropathies (SpA). A related question is whether second-line agents such as methotrexate (MTX) can improve axial inflammation and functional measures if administered early in disease. The SpA are a cluster of inflammatory arthridites encompassing ankylosing spondylitis (AS), psoriatic arthritis (PsA), Reiter's syndrome/reactive arthritis (ReA), and the arthritis associated with inflammatory bowel disease. These disorders share similar clinical and immunogenetic features including axial arthritis and enthesopathy, a general predilection for males and patients positive for the MHC class I alleles, the absence of rheumatoid factor, and association with infections of the intestinal and genitourinary tracts. Reclassification of SpA based on axial or peripheral involvement may be more relevant from a pathophysiologic and therapeutic perspective than the current stratification, given the strong association between axial disease and the HLAB27 allele and the relative resistance of axial disease to conventional anti-inflammatory therapy. | lld:pubmed |
| pubmed-article:11564371 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11564371 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11564371 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11564371 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11564371 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11564371 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11564371 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11564371 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11564371 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11564371 | pubmed:issn | 1523-3774 | lld:pubmed |
| pubmed-article:11564371 | pubmed:author | pubmed-author:RitchlinC TCT | lld:pubmed |
| pubmed-article:11564371 | pubmed:author | pubmed-author:DaikhB EBE | lld:pubmed |
| pubmed-article:11564371 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11564371 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:11564371 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11564371 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11564371 | pubmed:pagination | 399-403 | lld:pubmed |
| pubmed-article:11564371 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:meshHeading | pubmed-meshheading:11564371... | lld:pubmed |
| pubmed-article:11564371 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11564371 | pubmed:articleTitle | Recent advances in the treatment of the seronegative spondyloarthropathies. | lld:pubmed |
| pubmed-article:11564371 | pubmed:affiliation | Allergy/Immunology and Rheumatology Unit, Strong Memorial Hospital/University of Rochester Medical Center, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA. christopher_ritchlin@urmc.rochester.edu | lld:pubmed |
| pubmed-article:11564371 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11564371 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11564371 | lld:pubmed |
